Postoperative or Post‑Traumatic Infections with O.R. Procedures with MCC DRG Reimbursement

DRG 856 encompasses postoperative or post-traumatic infections requiring operating room procedures and presence of a Major Complication or Comorbidity, reflecting complex surgical and medical needs. This matters for inpatient reimbursement because the higher clinical severity and operative resource use drive elevated Medicare payment relative to lower-severity infection Diagnosis-Related Groups.

DRG 856 Overview

DRG 856 covers inpatient admissions for postoperative or post-traumatic infections that require an operating room procedure and are complicated by a Major Complication or Comorbidity. Typical cases include deep surgical site infections, infected hardware removals, or necrotizing soft tissue infections requiring operative debridement. This Diagnosis-Related Group is high-cost due to operative intervention, extended antimicrobial therapy, and intensive postoperative care needs. It is important for Medicare payment because the presence of a Major Complication or Comorbidity elevates reimbursement relative to less-complex infection groups.

Across commercial payers the observed negotiated rates span from roughly $370 to $160K, with payer means ranging from $39K (Blue Cross Blue Shield) to $74K (Cigna and Aetna). The widest spread is seen between the minimum and maximum values across payers (about $160K). See the table and chart below for payer-level detail and percentile breakdowns.

The CMS 2023 data reflect national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below presents average total payment ($41.6k), average submitted covered charges ($189.1k), average Medicare payment ($35.4k), and total discharges (7.3k).

Alaska Benchmarks

Across payers in Alaska for DRG 856, negotiated means range from $71K (Blue Cross Blue Shield) to $110K (Cigna), with Anthem matching BCBS at $71K. Cigna shows the widest spread in the state (min $59K to max $180K) and a mean that meaningfully exceeds typical national medians for this DRG. See the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna at $110K (range up to $180K); Lowest payer: Blue Cross Blue Shield at $71K.
Alaska’s mean rates skew higher than national medians for this DRG, with Cigna notably above the national Cigna mean and BCBS fixed at a lower, flat $71K.

Acute surgical intervention and antimicrobial strategy trials: randomized or prospective cohort studies comparing operative approaches (e.g., timing of re-operation, extent of debridement, use of staged procedures) combined with different empiric-to-targeted antimicrobial regimens in adults with severe postoperative or post-traumatic deep surgical site infections and organ/space infections complicated by major complications (MCC). These studies enroll inpatients in the immediate perioperative period to evaluate short-term outcomes such as infection control, need for additional O.R. procedures, ICU utilization, and in-hospital mortality, providing evidence on which acute management pathways most effectively control infection while minimizing repeat operations. Results inform surgeons, infectious disease teams, and payers about resource intensity, potential to reduce length of stay and readmissions, and appropriate coding and reimbursement considerations for complex operative infection care.
Comparative effectiveness and bundled-care pathway studies: pragmatic trials or observational comparative-effectiveness research assessing multidisciplinary care bundles (standardized surgical protocols, antimicrobial stewardship, wound care pathways, and early rehabilitation) versus usual care for patients with postoperative or post-traumatic infections requiring O.R. procedures and presenting with MCC. These studies target heterogeneous inpatient populations (orthopedic prosthetic joint infections, intra-abdominal post-op infections, complex soft-tissue trauma infections) and examine outcomes such as number of reoperations, days of parenteral antibiotics, total hospital costs, and complication rates; they aim to identify which bundle components drive improved outcomes. Evidence from these studies is relevant to hospital administrators and payers for designing clinically effective, cost-conscious pathways that can reduce variation, lower complication-related expenditures, and support DRG-level care management.
Post-discharge outcomes, rehabilitation, and health services research: longitudinal cohort studies or registry-based analyses following survivors of complex postoperative/post-traumatic infections with MCC after hospital discharge to evaluate long-term functional recovery, durable infection eradication, outpatient antibiotic use, device removal/reimplantation rates, and unplanned readmissions. These investigations often focus on high-risk subgroups (patients needing long-term intravenous therapy, those with prosthetic devices, or patients with multiple comorbidities) to characterize drivers of late complications, durable quality of life, and total episode-of-care costs. Findings are critical for payers and case managers to plan post-acute support, outpatient antibiotic administration resources, and to model total cost implications beyond the index hospitalization that influence bundled payment arrangements and resource allocation decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$42K	$190K	$35K	7.3K

Patient Population

This DRG population typically includes a mix of Medicare and commercial enrollees, but volume often skews toward Medicare-age patients given the higher hospitalization rates in older adults. Commercial (working-age) patients are also represented, resulting in a mixed-age cohort. Payer mix therefore commonly reflects a substantial Medicare share alongside private/commercial coverage.

Alaska Benchmarks

Key Insights for Alaska

Highest payer: Cigna at $110K (range up to $180K); Lowest payer: Blue Cross Blue Shield at $71K.
Alaska’s mean rates skew higher than national medians for this DRG, with Cigna notably above the national Cigna mean and BCBS fixed at a lower, flat $71K.

Acute surgical intervention and antimicrobial strategy trials: randomized or prospective cohort studies comparing operative approaches (e.g., timing of re-operation, extent of debridement, use of staged procedures) combined with different empiric-to-targeted antimicrobial regimens in adults with severe postoperative or post-traumatic deep surgical site infections and organ/space infections complicated by major complications (MCC). These studies enroll inpatients in the immediate perioperative period to evaluate short-term outcomes such as infection control, need for additional O.R. procedures, ICU utilization, and in-hospital mortality, providing evidence on which acute management pathways most effectively control infection while minimizing repeat operations. Results inform surgeons, infectious disease teams, and payers about resource intensity, potential to reduce length of stay and readmissions, and appropriate coding and reimbursement considerations for complex operative infection care.
Comparative effectiveness and bundled-care pathway studies: pragmatic trials or observational comparative-effectiveness research assessing multidisciplinary care bundles (standardized surgical protocols, antimicrobial stewardship, wound care pathways, and early rehabilitation) versus usual care for patients with postoperative or post-traumatic infections requiring O.R. procedures and presenting with MCC. These studies target heterogeneous inpatient populations (orthopedic prosthetic joint infections, intra-abdominal post-op infections, complex soft-tissue trauma infections) and examine outcomes such as number of reoperations, days of parenteral antibiotics, total hospital costs, and complication rates; they aim to identify which bundle components drive improved outcomes. Evidence from these studies is relevant to hospital administrators and payers for designing clinically effective, cost-conscious pathways that can reduce variation, lower complication-related expenditures, and support DRG-level care management.
Post-discharge outcomes, rehabilitation, and health services research: longitudinal cohort studies or registry-based analyses following survivors of complex postoperative/post-traumatic infections with MCC after hospital discharge to evaluate long-term functional recovery, durable infection eradication, outpatient antibiotic use, device removal/reimplantation rates, and unplanned readmissions. These investigations often focus on high-risk subgroups (patients needing long-term intravenous therapy, those with prosthetic devices, or patients with multiple comorbidities) to characterize drivers of late complications, durable quality of life, and total episode-of-care costs. Findings are critical for payers and case managers to plan post-acute support, outpatient antibiotic administration resources, and to model total cost implications beyond the index hospitalization that influence bundled payment arrangements and resource allocation decisions.

OpenPayer

Summary & Overview

Postoperative or Post-Traumatic Infections with O.R. Procedures with MCC: Inpatient Reimbursement Overview

DRG 856 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes